Clinical Trial Update: Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the BRd regimen (bendamustine, lenalidomide, and dexamethasone) as second-line therapy for relapsed or refractory multiple myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bendamustine (Bendamustine)
• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)

Snippet

Sponsor: Cantonal Hospital of St. Gallen | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED